Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult overactive bladder (OAB) patients who present with OAB symptoms, including urinary frequency \>= 8 per day and urgency urinary incontinence \>=1 per day~Exclusion Criteria:~* Patients with conditions that would contraindicate for fesoterodine use, e.g, hypersensitivity to the active substance (fesoterodine) or to peanut or soya or any of the excipients, urinary retention, and gastric retention.~* Patients with significant hepatic and renal disease or other significant unstable diseases.~* OAB symptoms caused by neurological conditions, known pathologies of urinary tract, etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fesoterodine (Type: EXPERIMENTAL): Tablets
- Placebo (Type: PLACEBO_COMPARATOR): Tablets and capsules
- Tolterodine (Type: ACTIVE_COMPARATOR): Capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).